Hepagene Therapeutics to Present at the European Association for the Study of the Liver (EASL) Congress 2023
- Written by PR Newswire
SHANGHAI, May 25, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today announced that Hepagene will present two posters highlighting the preclinical and clinical development for its two non-alcoholic steatohepatitis (NASH)...